Business
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00 am EDT Two Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD expected to initiate in 2026 Industry leader Neil Kumar, Ph.D., Founder and CEO of BridgeBio, appointed to Maze Board of Directors Strong balance sheet with $360.0 million in cash, cash equivale
About this update from Bridgebio Pharma, Inc.
[{"type":"image","alt":"Maze Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Maze Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":189,"height":191,"url":"https://media.zenfs.com/en/globenewswire.com/57257613842a42ee3dc08323998b9e45"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Hg_UPK_c__tx4wmkY4a68g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2NA--/https://media.zenfs.com/en/globenewswire.com/57257613842a42ee3dc08323998b9e45","width":189,"height":191},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/Hg_UPK_c__tx4wmkY4a68g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2NA--/https://media.zenfs.com/en/globenewswire.com/57257613842a42ee3dc08323998b9e45","width":189,"height":191}},"lazy":false},{"type":"text","content":"Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00 am EDT","length":227,"tagName":"p"},{"type":"text","content":"Two Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD expected to initiate in 2026","length":106,"tagName":"p"},{"type":"text","content":"Industry leader Neil Kumar, Ph.D., Founder and CEO of BridgeBio, appointed to Maze Board of Directors","length":101,"tagName":"p"},{"type":"text","content":"Strong balance sheet with $360.0 million in cash, cash equivalents and marketable securities; expected cash runway into 2028","length":124,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for the fourth quarter and year ended December 31, 2025, highlighting recent progress and business updates.","length":382,"tagName":"p"},{"type":"text","content":"“We are proud of the progress that Maze achieved in 2025 and have already carried our strong record of execution into the new year, as evidenced by today’s positive topline data from our Phase 2 HORIZON trial of MZE829 in broad AMKD,” said Jason Coloma, Ph.D., chief executive officer of Maze. “We look forward to advancing MZE829 into a pivotal program and to initiating our two Phase 2 trials ...